I now have all the information needed to write a comprehensive answer. Let me compile it.
Here is a comprehensive overview of MgSO₄ and the management of preterm labour, based on Creasy & Resnik's Maternal-Fetal Medicine, Goodman & Gilman's Pharmacological Basis of Therapeutics, and other authoritative sources.
Preterm Labour - Overview
Preterm labour is defined as uterine contractions with cervical change occurring between 20 and 37 weeks' gestation. It is the leading cause of perinatal morbidity and mortality worldwide.
Diagnosis is confirmed by:
- Regular painful/painless uterine contractions
- Cervical dilation ≥3 cm or effacement ≥80%
- Adjunctive tests: transvaginal ultrasound (TVU) cervical length < 30 mm or positive fetal fibronectin (fFN) in cervicovaginal fluid before 34 weeks
Overdiagnosis occurs in 40-70% of suspected cases; fFN and TVU reduce false positives - Creasy & Resnik's MFM, p.897
Tocolysis - Goals and Limitations
The primary goal of tocolysis is to delay delivery by 48 hours - long enough to:
- Administer antenatal corticosteroids (betamethasone/dexamethasone) for fetal lung maturation
- Transfer the mother to a tertiary care center (in-utero transfer)
- Possibly allow MgSO₄ neuroprotection to be administered
Tocolytic agents delay delivery in approximately 80% of women, but neither prevent premature birth nor improve adverse fetal outcomes such as RDS. - Goodman & Gilman, p.1904
Maintenance tocolysis (continued suppression after acute treatment) does not reduce preterm birth rates and is not recommended. - Creasy & Resnik's MFM, p.906
Tocolytic Agents
| Agent | Class | Delay 48h | Notes |
|---|
| Nifedipine | Ca²⁺ channel blocker | Yes | Preferred; fewer side effects |
| Atosiban | Oxytocin receptor antagonist | Yes | Widely used in Europe; not FDA-approved in US |
| β-mimetics (ritodrine, terbutaline) | β-adrenergic agonists | Yes | Effective but significant cardiovascular side effects |
| Indomethacin | COX inhibitor | Uncertain | Limited data; risk of premature ductus closure |
| MgSO₄ | Magnesium salt | Not supported | Cochrane reviews conclude it is ineffective as tocolytic |
The Cochrane analyses concluded that MgSO₄ and oxytocin receptor antagonists are ineffective as tocolytic agents. - Creasy & Resnik's MFM, p.901
Contraindications to Tocolysis
Maternal:
- Severe preeclampsia/gestational hypertension
- Antepartum haemorrhage / abruption
- Chorioamnionitis (infection)
- Significant maternal cardiac disease
Fetal:
- Gestational age >37 weeks
- Fetal demise or lethal anomaly
- Evidence of fetal compromise requiring prompt delivery
MgSO₄ in Preterm Labour - Its Actual Role: Fetal Neuroprotection
Although MgSO₄ is not effective as a tocolytic, it has a well-established role as fetal neuroprotection before very preterm birth.
Mechanism
Magnesium sulfate stabilizes:
- Vascular tone in the fetal brain
- Reduces reperfusion injury
- Reduces cytokine-mediated neurological injury
Evidence
- Multiple observational studies and RCTs show maternal MgSO₄ administration reduces the risk of cerebral palsy (CP) in survivors born preterm
- The NICHD MFMU Network RCT (Rouse et al., n=2241): demonstrated a significant reduction in the rate of moderate or severe CP
- The PREMAG trial (Marret et al.): MgSO₄ before 33 weeks showed significant reduction in late death or gross motor dysfunction at 2 years of age
- The ACTOMgSO₄ trial (Crowther et al., n=1062): lower incidence of CP (6.8% vs. 8.2%), though not statistically significant, with no serious harm
- ACOG/SMFM joint statement (2010): recommends MgSO₄ for fetal neuroprotection in women at risk for imminent preterm delivery at <32 weeks
"ACOG Committee on Obstetric Practice and SMFM issued a joint statement in 2010 recommending the use of magnesium sulfate for fetal neuroprotection before 32 weeks." - Creasy & Resnik's MFM, p.1800
Dosing (Neuroprotection Protocol)
- Loading dose: 4 g IV over 20-30 minutes
- Maintenance dose: 1 g/hour IV
- Treatment continued until delivery or for up to 24 hours
- Gestational age cutoff typically <32 weeks (some protocols use <34 weeks)
MgSO₄ Toxicity and Monitoring
Since MgSO₄ is excreted entirely by the kidneys, toxicity is a serious concern - especially with renal impairment.
| Serum Mg²⁺ Level | Effect |
|---|
| 4-7 mEq/L (therapeutic) | Neuroprotection / anticonvulsant |
| 7-10 mEq/L | Loss of patellar reflexes (first sign of toxicity) |
| 10-13 mEq/L | Respiratory depression |
| >15 mEq/L | Cardiac arrest |
Monitoring during infusion:
- Patellar (knee-jerk) reflexes - must be present
- Respiratory rate ≥12 breaths/min
- Urine output ≥25-30 mL/hour
- Serum Mg levels if clinically indicated
Antidote: 10 mL of 10% calcium gluconate IV (1 g) - reverses magnesium toxicity within minutes.
Other Key Management Steps in Preterm Labour
1. Antenatal Corticosteroids (ACS)
- Betamethasone 12 mg IM x 2 doses 24 hours apart, OR Dexamethasone 6 mg IM x 4 doses 12 hours apart
- Reduces incidence of RDS, IVH (intraventricular haemorrhage), PVL, and neonatal mortality
- Indicated at 24-34 weeks; may be considered 34-36+6 weeks (late preterm)
- A single rescue course may be given if ≥14 days have elapsed and delivery is still imminent
2. GBS Prophylaxis
- If GBS status unknown or positive: Penicillin G IV (or ampicillin)
- Reduces risk of early-onset neonatal GBS sepsis
3. Regionalized Care / Transfer
- Transfer to Level III/IV NICU center if <32 weeks (in-utero transfer preferred)
4. Adjunctive Interventions
- Progesterone (17-OHPC or vaginal progesterone): for prevention in high-risk women (prior spontaneous preterm birth or short cervix), not for acute treatment
- Cervical cerclage: for cervical incompetence, not for active preterm labour
Summary Table: MgSO₄ in Preterm Labour
| Role | Evidence | Recommended? |
|---|
| Tocolysis (stopping contractions) | Cochrane meta-analyses: ineffective | ❌ Not recommended |
| Fetal neuroprotection (prevent CP) | Multiple large RCTs, ACOG/SMFM endorsed | ✅ Recommended <32 weeks |
| Eclampsia prophylaxis (co-existing pre-eclampsia) | Gold standard, strong RCT evidence | ✅ Standard of care |
Recent evidence (2024-2025): A
2025 meta-analysis in Women Health comparing MgSO₄ vs. nifedipine for tocolysis confirmed that
nifedipine was superior to MgSO₄ for tocolytic efficacy, further supporting the shift away from MgSO₄ as a first-line tocolytic. A
2024 systematic review in BMC Pregnancy Childbirth comparing nifedipine with ritodrine, nitroglycerine, and magnesium sulfate for preterm labour management similarly found nifedipine to be the preferred agent.